# Sudarshan Pharma Industries share price today (Sudarshan Pharma Industries Ltd, NSE: SUDARSHAN)

> Sudarshan Pharma Industries share price today: ₹35.84 at the NSE close on 30 October 2026, up 32.6% in a year. Sudarshan Pharma Industries (NSE: SUDARSHAN) trades at a P/E of 31.9 and has closed between ₹20.00 and ₹41.82 over the past 52 weeks. > Sudarshan Pharma Industries Ltd's earnings have grown faster than its share price. Earnings per share grew +47.0% in a year while the price moved +32.6%. SUDARSHAN · Trading · data as of 30 October 2026. Page: https://www.sectoralpha.in/stocks/sudarshan-pharma-industries-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹35.84 (+32.6% in a year)
- P/E: 31.9× (higher than 50% of the last 3.6 years)
- Revenue (Sep 2026): ₹217 Cr (+28.5% on a year ago)
- Profit (Sep 2026): ₹7.8 Cr (+101.0% on a year ago)
- Operating margin: 9.5% (+4.0 points on a year ago)
- ROCE: 15%, FY26
- ROIC: 9.2%, against a 12.0% cost of capital: −2.8 points
- Profit that came in as cash: −56%, last 3 years

The main question: profits are rising, but only −56% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Sudarshan Pharma Industries share price today? Sudarshan Pharma Industries Ltd's share price was ₹35.84 at the close on 30 October 2026. It has been rising for 27 weeks. That is 4.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹20 and ₹42, and at that close it sat 73% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 3 weeks running. Over the last 3.6 years the share price moved +473% while the NIFTY 500 moved +53%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sudarshan Pharma Industries this quarter? 1 points in one quarter and profit up on a year earlier for 4 quarters in a row. 1. Revenue up on a year earlier for 6 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹217 crore, +28.5% on a year earlier. 2. Promoters cut their stake by 1.1 points in one quarter From 58.9% to 57.8% in the September 2026 quarter. 3. Profit up on a year earlier for 4 quarters in a row In the September 2026 quarter profit was ₹8 crore, +101% on a year earlier. ## What are Sudarshan Pharma Industries' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Sudarshan Pharma Industries reported revenue of ₹217 crore, up 28.5% from ₹169 crore a year earlier, and a profit of ₹7.78 crore, up 101.0% from ₹3.87 crore. ### Sudarshan Pharma Industries results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹217 crore | ₹169 crore | +28.5% |
| Profit | ₹7.78 crore | ₹3.87 crore | +101.0% |
| Earnings per share | ₹0.32 | ₹0.17 | +88.2% |
| Operating margin | 9.5% | 5.5% | +4.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Sudarshan Pharma Industries share price history? Sudarshan Pharma Industries closed at ₹35.84 on 30 October 2026, up 32.6% from ₹27.03 a year earlier (31 October 2025) and up 341.4% over three years. Its highest weekly close since March 2023 was ₹48.80 on 10 January 2025. ### Sudarshan Pharma Industries share price: then and now

| When | Close | Change to 30 Oct 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹31.25 | +14.7% |
| 1 month ago · 1 Oct 2026 | ₹37.24 | −3.8% |
| 1 year ago · 31 Oct 2025 | ₹27.03 | +32.6% |
| 3 years ago · 27 Oct 2023 | ₹8.12 | +341.4% |
| Earliest weekly close in our records · 24 Mar 2023 | ₹6.26 | +472.5% |
| Highest weekly close since March 2023 · 10 Jan 2025 | ₹48.80 | −26.6% |
| Lowest weekly close since March 2023 · 31 Mar 2023 | ₹5.58 | +542.3% |
| 52-week high (weekly close) · 24 Jul 2026 | ₹41.82 | −14.3% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹20.00 | +79.2% |

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes. (171 weekly closes from 24 March 2023 to 30 October 2026.)

## What is the latest news on Sudarshan Pharma Industries? 30 Oct 2026: Sudarshan Pharma Industries closed at ₹35.84, up 14.7% on the week and down 3.8% on the month. Results for July to September 2026: Revenue up 28.5% and profit up 101.0% on a year earlier. ## What dividend does Sudarshan Pharma Industries pay? Sudarshan Pharma Industries has paid no dividend on the NSE since its first NSE close in our records (24 March 2023), the start of the period we checked. Not in its latest year. Sudarshan Pharma Industries Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 1 of its last 7 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Sudarshan Pharma Industries on? Sudarshan Pharma Industries is on one of our India lists: Penny stocks. [Penny stocks Earnings growth, 12 months (%): 53.25](https://www.sectoralpha.in/penny-stocks-india)

## Is Sudarshan Pharma Industries profitable? Sudarshan Pharma Industries Ltd earned ₹7.8 Cr of net profit in the Sep 2026 quarter, +101.0% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹23.0 Cr. Over 6 years profit has grown 68.6% a year on average. That is 3.6% of the quarter's revenue. The same quarter a year earlier earned ₹3.9 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹23.0 Cr (+43.8% on the year before). Why profit moved: revenue changed +28.5% on a year earlier and the margin moved +4.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +60.2% and revenue +32.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Sudarshan Pharma Industries make, and is it growing? Sudarshan Pharma Industries Ltd reported ₹217 Cr of revenue in the Sep 2026 quarter, +28.5% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 6 years it has grown 29.7% a year on average. The last full year, FY26, came in at ₹703 Cr. The last four reported quarters add to ₹780 Cr. FY26 revenue was ₹703 Cr, +39.2% on the year before. Recent pace: the last four quarters grew +32.6% on average, against 29.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +31.9%, against +35.7% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +59.7%, against +94.2% a year (rolling over). ## How much of every ₹100 of sales does Sudarshan Pharma Industries keep? Sudarshan Pharma Industries Ltd's operating margin was 9.5% in the Sep 2026 quarter, 4.0 percentage points higher than the same quarter a year ago. Across 7 years it has been between 3.1% and 8.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +4.0 percentage points on the year while gross margin changed +5.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Sudarshan Pharma Industries' profit turning into cash? Over the last 3 years Sudarshan Pharma Industries Ltd's operations used more cash than they brought in, so cash conversion was −56%, a gap worth watching. In FY26 its operations used ₹2.0 Cr of cash, against ₹23.0 Cr of profit. After ₹40.0 Cr of spending on assets, free cash was −₹42.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why −56% of profit came in as cash: the cash cycle got 67 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 67 days longer. The next section looks at where the cash is stuck. ## Where does Sudarshan Pharma Industries' cash go? Sudarshan Pharma Industries Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 139 days in FY26, up from 72 days in FY21. It spent ₹94.0 Cr on assets over the last 3 years. Customers take 121 days to pay, and stock sits for 129 days on average. At FY26 sales of ₹703 Cr, each day of that cycle ties up about ₹1.9 Cr, so roughly ₹268 Cr is tied up in the business at any time. FY26: customers took 121 days to pay and stock sat for 129 days, about 4.2 months of sales sitting as stock, for a full cycle of 139 days, longer than FY21's 72. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 129 days. Customers pay about 121 days after that. Suppliers are paid at 111 days. Together that makes the 139-day cycle. Spending on assets: ₹94.0 Cr over the last 3 years, against ₹7.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Sudarshan Pharma Industries' P/E ratio, and how does it compare with its own history? Sudarshan Pharma Industries Ltd's P/E is 31.9×, in the middle of its own history: higher than 50% of past readings. Its usual P/E (the middle reading) is 32.1×, over 3.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹1.18. Why the multiple is where it is: over the past year earnings per share moved +47.0% while the price moved +32.6%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +64.0% a year; about +56.0% a year came from earnings growth and about +8.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Sudarshan Pharma Industries business getting better or worse? Sudarshan Pharma Industries Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Sudarshan Pharma Industries earn on its capital? Sudarshan Pharma Industries Ltd earned a ROCE of 15% in FY26. That is up from a low of 14% in FY24. Its return on capital used (ROIC) is 2.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 3.3% net margin and 1.10× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 3.3% net margin × 1.10× asset turnover × 4.14× leverage (assets divided by equity) ≈ 15.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 9.2% − 12.0% = −2.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Sudarshan Pharma Industries have too much debt? Sudarshan Pharma Industries Ltd has total debt of ₹392 Cr against shareholder equity of ₹196 Cr as of Sep 2026, so its debt is 2.00× its equity. Year by year, that ratio went from 0.74 in FY19 to 1.83 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Sudarshan Pharma Industries shareholding pattern? Foreign institutions raised their stake in Sudarshan Pharma Industries Ltd by 8.9 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 21.9% of the company. Promoters moved +0.4 points over the same period, to 57.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why the owners changed: foreign institutions drove it (+8.9 points). They raised their stake step by step. ## How far is Sudarshan Pharma Industries from balance-sheet trouble? For Sudarshan Pharma Industries Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sudarshan Pharma Industries rank in its industry? 58.7 out of 100, rank 12 of 63 in Trading, with 85% of the evidence available. Sudarshan Pharma Industries Ltd scores 58.7 out of 100 against the 63 companies it is compared with in Trading, ranking 12. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 22.5 + 13.8 + 11.2 + 11.2 = 58.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sudarshan Pharma Industries compared with? Sudarshan Pharma Industries ranks 12 of 63 Trading companies on the 4-Factor Sector Score, with 58.7 out of 100. 1. [Mangalam Global Enterprise Ltd](https://www.sectoralpha.in/stocks/mangalam-global-enterprise-ltd) MGEL · turning · Most evidence points up · 93% evidence 70.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 44.2% · Profit 8.2% · Operating margin change 0.7 points · 100% evidence Capital efficiency 14.6/25 · ROCE 17% · Operating margin 2.3% · 100% evidence Valuation 15.8/20 · P/E 14.6× · PEG 0.31 · 65% evidence Relative strength 17.2/20 · Lead over its industry 12.9% · Lead over NIFTY 500 25.7% · 1 year 18.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.5 + 14.6 + 15.8 + 17.2 = 70.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shankara Buildpro Ltd](https://www.sectoralpha.in/stocks/shankara-buildpro-ltd) BUILDPRO · quiet · Too little evidence to rank firmly · 59% evidence 64.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.0/43.75 · Revenue 26.3% · Profit 41.9% · Operating margin change -0.2 points · 88% evidence Capital efficiency 21.5/31.25 · ROCE 39% · Operating margin 3.2% · 100% evidence Valuation 13.4/25 · P/E 16× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 30 + 21.5 + 13.4 = 64.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Ivalue Infosolutions Ltd](https://www.sectoralpha.in/stocks/ivalue-infosolutions-ltd) IVALUE · quiet · Evidence leans up · 74% evidence 64.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 5.4% · Profit 22.1% · Operating margin change 5.6 points · 88% evidence Capital efficiency 19.8/25 · ROCE 25.4% · Operating margin 10% · 100% evidence Valuation 15.7/20 · P/E 10× · PEG 0.43 · 65% evidence Relative strength 8.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -18.6% · 1 year -31.1% · 25% evidence · 3 of 12 weeks ahead Exact sum: 20.7 + 19.8 + 15.7 + 8.1 = 64.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Maxgrow India Ltd](https://www.sectoralpha.in/stocks/maxgrow-india-ltd) Too little evidence to rank firmly · 53% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit 100% · Operating margin change 0.8 points · 62% evidence Capital efficiency 16.4/25 · ROCE 23.5% · Operating margin 2.7% · 95% evidence Valuation 11.5/20 · P/E 1.2× · PEG n/a · 15% evidence Relative strength 12.4/20 · Lead over its industry n/a · Lead over NIFTY 500 136% · 1 year n/a · 25% evidence Exact sum: 23.9 + 16.4 + 11.5 + 12.4 = 64.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [Nupur Recyclers Ltd](https://www.sectoralpha.in/stocks/nupur-recyclers-ltd) NRL · leader · Evidence leans up · 78% evidence 63.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 40.6% · Profit 29.8% · Operating margin change 3.6 points · 83% evidence Capital efficiency 15.3/25 · ROCE 15.1% · Operating margin 11.6% · 76% evidence Valuation 7.6/20 · P/E 64.4× · PEG n/a · 50% evidence Relative strength 19.9/20 · Lead over its industry 86.1% · Lead over NIFTY 500 100.5% · 1 year 134.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 15.3 + 7.6 + 19.9 = 63.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Arisinfra Solutions Ltd](https://www.sectoralpha.in/stocks/arisinfra-solutions-ltd) ARIS · breaking out · Too little evidence to rank firmly · 56% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.5/35 · Revenue 45.3% · Profit 100% · Operating margin change 2 points · 83% evidence Capital efficiency 13.5/25 · ROCE 15.6% · Operating margin 11% · 76% evidence Valuation 10.7/20 · P/E 17.2× · PEG n/a · 15% evidence Relative strength 10.9/20 · Lead over its industry n/a · Lead over NIFTY 500 16.6% · 1 year -14.9% · 25% evidence · 11 of 12 weeks ahead Exact sum: 26.5 + 13.5 + 10.7 + 10.9 = 61.6 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 7. [Bhatia Communications & Retail (India) Ltd](https://www.sectoralpha.in/stocks/bhatia-communications-retail-indialtd) Evidence leans up · 68% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 49% · Profit 45.5% · Operating margin change 0.3 points · 83% evidence Capital efficiency 18.4/25 · ROCE 21.3% · Operating margin 5.3% · 95% evidence Valuation 9.2/20 · P/E 22.8× · PEG n/a · 50% evidence Relative strength 11.5/20 · Lead over its industry n/a · Lead over NIFTY 500 30.1% · 1 year n/a · 25% evidence Exact sum: 21.7 + 18.4 + 9.2 + 11.5 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [DC Infotech & Communication Ltd](https://www.sectoralpha.in/stocks/dc-infotech-communication-ltd) DCI · breaking out · Evidence leans up · 81% evidence 60.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 29.1% · Profit 41.9% · Operating margin change 0.4 points · 88% evidence Capital efficiency 16.5/25 · ROCE 23% · Operating margin 4.8% · 100% evidence Valuation 13.4/20 · P/E 24.6× · PEG 0.82 · 100% evidence Relative strength 11.1/20 · Lead over its industry n/a · Lead over NIFTY 500 20.1% · 1 year n/a · 25% evidence · 6 of 6 weeks ahead Exact sum: 19.3 + 16.5 + 13.4 + 11.1 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [SG Mart Ltd](https://www.sectoralpha.in/stocks/sg-mart-ltd) SGMART · leader · Evidence leans up · 93% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue 9.7% · Profit 26.7% · Operating margin change 3 points · 100% evidence Capital efficiency 11.6/25 · ROCE 10.2% · Operating margin 4.6% · 100% evidence Valuation 7.9/20 · P/E 71.1× · PEG 1.81 · 65% evidence Relative strength 18.3/20 · Lead over its industry 47.1% · Lead over NIFTY 500 60.5% · 1 year 146.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.3 + 11.6 + 7.9 + 18.3 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Tembo Global Industries Ltd](https://www.sectoralpha.in/stocks/tembo-global-industries-ltd) TEMBO · losing its lead · Evidence leans up · 71% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.6/35 · Revenue 34% · Profit 55.7% · Operating margin change 5 points · 83% evidence Capital efficiency 19.6/25 · ROCE 22.8% · Operating margin 16% · 76% evidence Valuation 11.2/20 · P/E 9.3× · PEG n/a · 15% evidence Relative strength 7.0/20 · Lead over its industry -19.2% · Lead over NIFTY 500 -8.7% · 1 year -20.8% · 100% evidence · 3 of 12 weeks ahead Exact sum: 21.6 + 19.6 + 11.2 + 7 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Rashi Peripherals Ltd](https://www.sectoralpha.in/stocks/rashi-peripherals-ltd) RPTECH · losing its lead · Evidence leans up · 78% evidence 59.3 out of 100 Growth Capital Valuation Relative
12. Sudarshan Pharma Industries Ltd this page SUDARSHAN · turning · Evidence leans up · 85% evidence 58.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 31.9% · Profit 59.7% · Operating margin change 4 points · 100% evidence Capital efficiency 13.8/25 · ROCE 15.1% · Operating margin 9.5% · 100% evidence Valuation 11.2/20 · P/E 31.9× · PEG 1.01 · 100% evidence Relative strength 11.2/20 · Lead over its industry n/a · Lead over NIFTY 500 20.2% · 1 year 32.6% · 25% evidence · 0 of 5 weeks ahead Exact sum: 22.5 + 13.8 + 11.2 + 11.2 = 58.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 13. [Singer India Ltd](https://www.sectoralpha.in/stocks/singer-india-ltd) SINGERIND · Evidence leans up · 61% evidence 58.0 out of 100 Growth Capital Valuation Relative
14. [Euro Pratik Sales Ltd](https://www.sectoralpha.in/stocks/euro-pratik-sales-ltd) EUROPRATIK · quiet · Evidence leans up · 64% evidence 57.5 out of 100 Growth Capital Valuation Relative
15. [Pramara Promotions Ltd](https://www.sectoralpha.in/stocks/pramara-promotions-ltd) PRAMARA · Too little evidence to rank firmly · 52% evidence 54.6 out of 100 Growth Capital Valuation Relative
16. [State Trading Corporation of India Ltd](https://www.sectoralpha.in/stocks/state-trading-corporation-of-india-ltd) STCINDIA · quiet · Too little evidence to rank firmly · 57% evidence 53.4 out of 100 Growth Capital Valuation Relative
17. [Patel Retail Ltd](https://www.sectoralpha.in/stocks/patel-retail-ltd) PATELRMART · turning · Evidence leans up · 64% evidence 53.2 out of 100 Growth Capital Valuation Relative
18. [Yogi Ltd](https://www.sectoralpha.in/stocks/yogi-ltd) YOGI · quiet · Evidence leans up · 64% evidence 51.2 out of 100 Growth Capital Valuation Relative
19. [Transchem Ltd](https://www.sectoralpha.in/stocks/transchem-ltd) TRANSCHEM · Too little evidence to rank firmly · 52% evidence 51.0 out of 100 Growth Capital Valuation Relative
20. [Prostarm Info Systems Ltd](https://www.sectoralpha.in/stocks/prostarm-info-systems-ltd) PROSTARM · breaking out · Evidence leans up · 64% evidence 50.8 out of 100 Growth Capital Valuation Relative
21. [Dhunseri Ventures Ltd](https://www.sectoralpha.in/stocks/dhunseri-ventures-ltd) DVL · breaking out · Evidence leans up · 78% evidence 50.6 out of 100 Growth Capital Valuation Relative
22. Bizotic Commercial Ltd losing its lead · Evidence leans up · 63% evidence 50.5 out of 100 Growth Capital Valuation Relative
23. BMW Ventures Ltd BMW · Too little evidence to rank firmly · 51% evidence 50.2 out of 100 Growth Capital Valuation Relative
24. [Cropster Agro Ltd](https://www.sectoralpha.in/stocks/cropster-agro-ltd) quiet · Evidence leans down · 65% evidence 49.1 out of 100 Growth Capital Valuation Relative
25. [MMTC Ltd](https://www.sectoralpha.in/stocks/mmtc-ltd) MMTC · quiet · Evidence leans down · 92% evidence 47.2 out of 100 Growth Capital Valuation Relative
26. [Shiv Aum Steels Ltd](https://www.sectoralpha.in/stocks/shiv-aum-steels-ltd) SHIVAUM · breaking out · Evidence leans down · 63% evidence 46.8 out of 100 Growth Capital Valuation Relative
27. [Blue Pearl Agriventures Ltd](https://www.sectoralpha.in/stocks/blue-pearl-agriventures-ltd) BPAGRI · Too little evidence to rank firmly · 51% evidence 43.8 out of 100 Growth Capital Valuation Relative
28. [Lloyds Enterprises Ltd](https://www.sectoralpha.in/stocks/lloyds-enterprises-ltd) LLOYDSENT · quiet · Evidence leans down · 71% evidence 43.1 out of 100 Growth Capital Valuation Relative
29. [Hexa Tradex Ltd](https://www.sectoralpha.in/stocks/hexa-tradex-ltd) HEXATRADEX · breaking out · Evidence leans down · 64% evidence 39.9 out of 100 Growth Capital Valuation Relative
30. [Shanti Overseas (India) Ltd](https://www.sectoralpha.in/stocks/shanti-overseas-indialtd) SHANTI · Evidence leans down · 61% evidence 39.3 out of 100 Growth Capital Valuation Relative
31. [Riddhi Siddhi Gluco Biols Ltd](https://www.sectoralpha.in/stocks/riddhi-siddhi-gluco-biols-ltd) turning · Evidence leans down · 83% evidence 38.9 out of 100 Growth Capital Valuation Relative
32. [Hardwyn India Ltd](https://www.sectoralpha.in/stocks/hardwyn-india-ltd) HARDWYN · basing · Evidence leans down · 86% evidence 38.8 out of 100 Growth Capital Valuation Relative
33. [Adani Enterprises Ltd](https://www.sectoralpha.in/stocks/adani-enterprises-ltd) ADANIENT · quiet · Evidence leans down · 93% evidence 38.1 out of 100 Growth Capital Valuation Relative
34. [PTC India Ltd](https://www.sectoralpha.in/stocks/ptc-india-ltd) PTC · quiet · Evidence leans down · 78% evidence 37.4 out of 100 Growth Capital Valuation Relative
35. [Le Merite Exports Ltd](https://www.sectoralpha.in/stocks/le-merite-exports-ltd) LEMERITE · Too little evidence to rank firmly · 59% evidence 36.8 out of 100 Growth Capital Valuation Relative
36. [Fabtech Technologies Ltd](https://www.sectoralpha.in/stocks/fabtech-technologies-ltd) FABTECH · quiet · Evidence leans down · 68% evidence 36.7 out of 100 Growth Capital Valuation Relative
37. [Uniphos Enterprises Ltd](https://www.sectoralpha.in/stocks/uniphos-enterprises-ltd) UNIENTER · turning · Too little evidence to rank firmly · 59% evidence 35.7 out of 100 Growth Capital Valuation Relative
38. Manbro Industries Ltd Too little evidence to rank firmly · 57% evidence 35.3 out of 100 Growth Capital Valuation Relative
39. Shah Foods Ltd quiet · Too little evidence to rank firmly · 53% evidence 35.3 out of 100 Growth Capital Valuation Relative
40. [BN Agrochem Ltd](https://www.sectoralpha.in/stocks/bn-agrochem-ltd) BNAGROCHEM · quiet · Most evidence points down · 64% evidence 34.1 out of 100 Growth Capital Valuation Relative
41. [Neueon Corporation Ltd](https://www.sectoralpha.in/stocks/neueon-corporation-ltd) NEUEON · quiet · Too little evidence to rank firmly · 56% evidence 33.3 out of 100 Growth Capital Valuation Relative
42. [Kothari Industrial Corporation Ltd](https://www.sectoralpha.in/stocks/kothari-industrial-corporation-ltd) KOTIC · quiet · Too little evidence to rank firmly · 53% evidence 32.9 out of 100 Growth Capital Valuation Relative
43. [Oswal Agro Mills Ltd](https://www.sectoralpha.in/stocks/oswal-agro-mills-ltd) OSWALAGRO · Too little evidence to rank firmly · 52% evidence 28.6 out of 100 Growth Capital Valuation Relative
44. [Susan Electricals India Ltd](https://www.sectoralpha.in/stocks/susan-electricals-india-ltd) quiet · Too little evidence to rank firmly · 36% evidence 61.2 out of 100 Growth Capital Valuation Relative
45. [Magnus Steel & Infra Ltd](https://www.sectoralpha.in/stocks/magnus-steel-infra-ltd) Too little evidence to rank firmly · 40% evidence 61.1 out of 100 Growth Capital Valuation Relative
46. [Vision Infra Equipment Solutions Ltd](https://www.sectoralpha.in/stocks/vision-infra-equipment-solutions-ltd) VIESL · breaking out · Too little evidence to rank firmly · 47% evidence 58.5 out of 100 Growth Capital Valuation Relative
47. [Q-Line Biotech Ltd](https://www.sectoralpha.in/stocks/q-line-biotech-ltd) QLINE · losing its lead · Too little evidence to rank firmly · 21% evidence 57.8 out of 100 Growth Capital Valuation Relative
48. Aayush Art and Bullion Ltd breaking out · Too little evidence to rank firmly · 48% evidence 57.1 out of 100 Growth Capital Valuation Relative
49. [HP Telecom India Ltd](https://www.sectoralpha.in/stocks/hp-telecom-india-ltd) HPTL · Too little evidence to rank firmly · 32% evidence 57.1 out of 100 Growth Capital Valuation Relative
50. [SK Minerals & Additives Ltd](https://www.sectoralpha.in/stocks/sk-minerals-additives-ltd) quiet · Too little evidence to rank firmly · 43% evidence 55.9 out of 100 Growth Capital Valuation Relative
51. [Aptus Pharma Ltd](https://www.sectoralpha.in/stocks/aptus-pharma-ltd) Too little evidence to rank firmly · 41% evidence 55.6 out of 100 Growth Capital Valuation Relative
52. [Mardia Samyoung Capillary Tubes Company Ltd](https://www.sectoralpha.in/stocks/mardia-samyoung-capillary-tubes-company-ltd) MSCTC · Too little evidence to rank firmly · 26% evidence 55.3 out of 100 Growth Capital Valuation Relative
53. [Proventus Agrocom Ltd](https://www.sectoralpha.in/stocks/proventus-agrocom-ltd) PROV · breaking out · Too little evidence to rank firmly · 39% evidence 54.1 out of 100 Growth Capital Valuation Relative
54. [Pervasive Commodities Ltd](https://www.sectoralpha.in/stocks/pervasive-commodities-ltd) breaking out · Too little evidence to rank firmly · 48% evidence 51.8 out of 100 Growth Capital Valuation Relative
55. [Monika Alcobev Ltd](https://www.sectoralpha.in/stocks/monika-alcobev-ltd) MONIKA · Too little evidence to rank firmly · 27% evidence 49.9 out of 100 Growth Capital Valuation Relative
56. [Onix Solar Energy Ltd](https://www.sectoralpha.in/stocks/onix-solar-energy-ltd) ONIXSOLAR · quiet · Too little evidence to rank firmly · 47% evidence 45.8 out of 100 Growth Capital Valuation Relative
57. Arvaya Healthcare Ltd ARVAYA · quiet · Too little evidence to rank firmly · 46% evidence 45.4 out of 100 Growth Capital Valuation Relative
58. [A-1 Ltd](https://www.sectoralpha.in/stocks/a-1-ltd) A1L · Too little evidence to rank firmly · 33% evidence 45.3 out of 100 Growth Capital Valuation Relative
59. [Satani Bearings Ltd](https://www.sectoralpha.in/stocks/satani-bearings-ltd) breaking out · Too little evidence to rank firmly · 42% evidence 42.9 out of 100 Growth Capital Valuation Relative
60. [Keto Motors Ltd](https://www.sectoralpha.in/stocks/keto-motors-ltd) quiet · Too little evidence to rank firmly · 42% evidence 40.9 out of 100 Growth Capital Valuation Relative
61. [Aerpace Industries Ltd](https://www.sectoralpha.in/stocks/aerpace-industries-ltd) breaking out · Too little evidence to rank firmly · 36% evidence 37.9 out of 100 Growth Capital Valuation Relative
62. [Prabhatam Infra Venture Ltd](https://www.sectoralpha.in/stocks/prabhatam-infra-venture-ltd) PRABHATAM · Too little evidence to rank firmly · 22% evidence 36.8 out of 100 Growth Capital Valuation Relative
63. [RRP Semiconductor Ltd](https://www.sectoralpha.in/stocks/rrp-semiconductor-ltd) RRP · Too little evidence to rank firmly · 42% evidence 34.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Trading](https://www.sectoralpha.in/sectors/trading), all 63 compared on one page. ## Which companies are close to Sudarshan Pharma Industries in size? Sudarshan Pharma Industries is the 28th largest of 59 Trading companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Patel Retail, Aptus Pharma and Vision Infra Equipment Solutions. Just below it: Shiv Aum Steels, Prostarm Info Systems and Maxgrow India. ### Trading companies close in size

1. [Patel Retail Ltd](https://www.sectoralpha.in/stocks/patel-retail-ltd) ₹799 crore
2. [Aptus Pharma Ltd](https://www.sectoralpha.in/stocks/aptus-pharma-ltd) ₹793 crore
3. [Vision Infra Equipment Solutions Ltd](https://www.sectoralpha.in/stocks/vision-infra-equipment-solutions-ltd) ₹782 crore
4. Sudarshan Pharma Industries Ltd ₹780 crore
5. [Shiv Aum Steels Ltd](https://www.sectoralpha.in/stocks/shiv-aum-steels-ltd) ₹742 crore
6. [Prostarm Info Systems Ltd](https://www.sectoralpha.in/stocks/prostarm-info-systems-ltd) ₹735 crore
7. [Maxgrow India Ltd](https://www.sectoralpha.in/stocks/maxgrow-india-ltd) ₹709 crore

[All 59 Trading companies, largest first](https://www.sectoralpha.in/sectors/trading#all-companies)

### Companies close in size in other industries

1. [Amines & Plasticizers Ltd](https://www.sectoralpha.in/stocks/amines-plasticizers-ltd) ₹782 crore · Speciality Chemicals
2. [Vision Infra Equipment Solutions Ltd](https://www.sectoralpha.in/stocks/vision-infra-equipment-solutions-ltd) ₹782 crore · Trading
3. Sudarshan Pharma Industries Ltd ₹780 crore
4. [Dhampur Bio Organics Ltd](https://www.sectoralpha.in/stocks/dhampur-bio-organics-ltd) ₹779 crore · Sugar
5. [Namo eWaste Management Ltd](https://www.sectoralpha.in/stocks/namo-ewaste-management-ltd) ₹778 crore · Recycling

## What else do people ask about Sudarshan Pharma Industries? ### What is Sudarshan Pharma Industries's share price today? Sudarshan Pharma Industries Ltd's share price is ₹35.84, +32.6% over the past year. The whole company is worth ₹927 Cr on the market. In the last 52 weeks it traded between ₹20 to ₹42; today it is 73% of the way up from the low, 4.6% above its 200-day average (as of 30 October 2026). ### What were Sudarshan Pharma Industries's latest quarterly results? Sudarshan Pharma Industries Ltd reported revenue of ₹217 Cr and net profit of ₹7.8 Cr for the Sep 2026 quarter. Revenue rose 28.5% and profit rose 101.0% compared with a year earlier. Earnings per share were ₹0.32. The operating margin was 9.5%, 4.0 percentage points higher than a year earlier (as of 30 October 2026). ### What is Sudarshan Pharma Industries's market cap? Sudarshan Pharma Industries Ltd's market capitalisation is ₹927 Cr at a share price of ₹35.84. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 30 October 2026). ### How is Sudarshan Pharma Industries performing? Sudarshan Pharma Industries Ltd's share price has been rising for 27 weeks. In its latest quarter, revenue rose 28.5% and profit rose 101.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 3 weeks running (as of 30 October 2026). ### Will Sudarshan Pharma Industries's share price go up? This page does not forecast Sudarshan Pharma Industries Ltd's share price. What it shows instead: the share price is ₹35.84, and it has been rising for 27 weeks. Its P/E of 31.9× is higher than 50% of its own last 4 years (as of 30 October 2026). ### Does Sudarshan Pharma Industries have too much debt? Yes, Sudarshan Pharma Industries Ltd has a lot of debt: its debt is 1.84× its equity, and its operating profit is 2 times its interest bill. FY26 borrowings were ₹285 Cr against equity of ₹155 Cr. Keep that borrowing in mind when reading the returns on this page (as of 30 October 2026). ### Where is Sudarshan Pharma Industries in its business cycle? Sudarshan Pharma Industries Ltd's FY26 operating margin was 7.0%, against a 7-year range of 3.1% to 8.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 9.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 30 October 2026). ### What could break the Sudarshan Pharma Industries story? The main question: profits are rising, but only −56% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 30 October 2026). ### Is Sudarshan Pharma Industries a stock worth studying right now? What the numbers show: Sudarshan Pharma Industries Ltd's earnings have grown faster than its share price. Earnings per share grew +47.0% in a year while the price moved +32.6%. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 30 October 2026). ## Lists

- Penny stocks: https://www.sectoralpha.in/penny-stocks-india

This is research, not advice. We’re not SEBI-registered.